NCT02461745 - Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions

Hepatitis C, Chronic

Interventions

DRUG

ombitasvir, paritaprevir/r, dasabuvir + ribavirin

VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) + RBV (ribavirin tablets) for 12 weeks

DRUG

ombitasvir, paritaprevir/r, dasabuvir

VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets)

Trial Locations (4)

Kaiser Permanente Medical Center, Los Angeles

Kaiser Permanente Medical Center, San Marcos

Kaiser Permanente Medical Center, San Diego

Kaiser Permanente Medical Center, Irvine